Carlo Solcia

Althea is the Pan-European largest independent provider of integrated healthcare technology management. We operate as an outsourced technological partner for the provision of managed services and multivendor maintenance of the entire medical equipment portfolio in public and private healthcare organisations. Across multiple technologies - from biomedical equipment to advanced diagnostic imaging & radiology. The business model of Althea is an outstanding combination of integrated solutions, OEM independence and deep knowledge of healthcare processes that leads to better patient care, cost efficiencies and value maximisation of healthcare providers, improving quality of life. Our skilled on-site biomedical teams perform advanced technical solutions independent of brands, technologies and equipment classes, delivering a single source of tailored and integrated services for customers’ needs. The Group manages more than 1.4 million medical devices in over 2,700 healthcare facilities across 16 countries. Our centres of excellence span the globe, leveraging the expertise of more than 2,500 engineers, technicians, administrators and customer service specialists. ALTHEA: WE UNLOCK THE POTENTIAL OF TECHNOLOGY WITH A COMMITMENT TO BETTER HEALTHCARE

Resono Ophthalmic is an innovative Italian company created in 2014 to develop and commercialize cutting-edge therapeutic devices for ophthalmology. The key feature of these devices is the Quantum Molecular Resonance treatment. QMR® is a patented technology which stimulates the natural regeneration of cells and tissue via low-power and high-frequency electric fields. Resono first applied this technique to treat Dry Eye Disease (DED) with Rexon-Eye®, a patented CE-marked medical device. So far, clinical trials in Italy and abroad have proved with evidence that Rexon-Eye® is a safe, effective, and long-term treatment option for all types of DED. The benefits of QMR in stimulating cell and tissue regeneration are currently understudying for the application in other eye diseases. For more information and technical details, visit our website. *QMR® is a registered trademark by Telea Electronic Engineering.

Lipogems’ vision is to bring responsible, effective medical technologies to physicians and patients. Lipogems strives to provide physicians and patients with adipose tissue solutions to help maintain or restore patient lifestyles and to improve quality of life and recovery times. These solutions may offer another option to those who may not want, or who are not candidates for, major, invasive surgery. Lipogems may also be used with surgery. Lipogems International has developed and patented a disposable sterile device (CE Marked Class IIa) for close-circuit, single-step processing of lipoaspirates. In the United States, Lipogems system is 510(k) cleared and is indicated for the harvest, concentration, and transfer of autologous adipose tissue. The system meets new FDA guidelines for minimal manipulation and is intended for homologous use. The company is based in Milan, Italy and Norcross, Georgia, USA. Lipogems is distributed in 27 countries around the world. Ethical Code: Through our Ethical Code and close collaboration with many important international research centers reinforce the integrity in our approach to healthcare professionals and patient care. Partnership to Make a Difference In Healthcare: Physicians, Surgeons, and Scientific Researchers to aim to improve Patients’ lives all over the world by providing Innovative Technologies and Medical solutions For more information, please visit www.lipogems.eu and www.understandlipogems.com and follow us on Facebook at Lipogems International.

Althea is the Pan-European largest independent provider of integrated healthcare technology management. We operate as an outsourced technological partner for the provision of managed services and multivendor maintenance of the entire medical equipment portfolio in public and private healthcare organisations. Across multiple technologies - from biomedical equipment to advanced diagnostic imaging & radiology. The business model of Althea is an outstanding combination of integrated solutions, OEM independence and deep knowledge of healthcare processes that leads to better patient care, cost efficiencies and value maximisation of healthcare providers, improving quality of life. Our skilled on-site biomedical teams perform advanced technical solutions independent of brands, technologies and equipment classes, delivering a single source of tailored and integrated services for customers’ needs. The Group manages more than 1.4 million medical devices in over 2,700 healthcare facilities across 16 countries. Our centres of excellence span the globe, leveraging the expertise of more than 2,500 engineers, technicians, administrators and customer service specialists. ALTHEA: WE UNLOCK THE POTENTIAL OF TECHNOLOGY WITH A COMMITMENT TO BETTER HEALTHCARE

Resono Ophthalmic is an innovative Italian company created in 2014 to develop and commercialize cutting-edge therapeutic devices for ophthalmology. The key feature of these devices is the Quantum Molecular Resonance treatment. QMR® is a patented technology which stimulates the natural regeneration of cells and tissue via low-power and high-frequency electric fields. Resono first applied this technique to treat Dry Eye Disease (DED) with Rexon-Eye®, a patented CE-marked medical device. So far, clinical trials in Italy and abroad have proved with evidence that Rexon-Eye® is a safe, effective, and long-term treatment option for all types of DED. The benefits of QMR in stimulating cell and tissue regeneration are currently understudying for the application in other eye diseases. For more information and technical details, visit our website. *QMR® is a registered trademark by Telea Electronic Engineering.

Lipogems’ vision is to bring responsible, effective medical technologies to physicians and patients. Lipogems strives to provide physicians and patients with adipose tissue solutions to help maintain or restore patient lifestyles and to improve quality of life and recovery times. These solutions may offer another option to those who may not want, or who are not candidates for, major, invasive surgery. Lipogems may also be used with surgery. Lipogems International has developed and patented a disposable sterile device (CE Marked Class IIa) for close-circuit, single-step processing of lipoaspirates. In the United States, Lipogems system is 510(k) cleared and is indicated for the harvest, concentration, and transfer of autologous adipose tissue. The system meets new FDA guidelines for minimal manipulation and is intended for homologous use. The company is based in Milan, Italy and Norcross, Georgia, USA. Lipogems is distributed in 27 countries around the world. Ethical Code: Through our Ethical Code and close collaboration with many important international research centers reinforce the integrity in our approach to healthcare professionals and patient care. Partnership to Make a Difference In Healthcare: Physicians, Surgeons, and Scientific Researchers to aim to improve Patients’ lives all over the world by providing Innovative Technologies and Medical solutions For more information, please visit www.lipogems.eu and www.understandlipogems.com and follow us on Facebook at Lipogems International.